GS-967 inhibits voltage-gated Na+ channels, exhibiting antiepileptic, anticonvulsant, ant anti-arrhythmic activities. GS-967 decreases the cardiac late Na+ current. In vivo, this compound decreases seizure frequency and improves survival rates. In rat hearts, GS-967 suppresses and prevents ventricular tachycardia and fibrillation.
| Cas No. | 1262618-39-2 |
|---|---|
| Purity | ≥98% |
| Formula | C14H7F6N3O |
| Formula Wt. | 347.22 |
| IUPAC Name | 6-[4-(Trifluoromethoxy)phenyl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine |
| Solubility | 10 mM in DMSO, insoluble in water |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Anderson LL, Thompson CH, Hawkins NA, et al. Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia. 2014 Aug;55(8):1274-83. PMID: 24862204.
Pezhouman A, Madahian S, Stepanyan H, et al. Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts. Heart Rhythm. 2014 Mar;11(3):492-501. PMID: 24291413.
Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm. 2013 Jul;10(7):1036-43. PMID: 23524321.
